First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

被引：0
|
作者：
Sonneveld, P. [1 ,2 ]
van der Holt, B.
Schmidt-Wolf, I. G. H.
Bertsch, U. [3 ]
el Jarari, L.
Salwender, Hans-Juergen
Zweegman, S. [1 ]
Vellenga, E. [1 ]
Schubert, J.
Blau, I. W.
Jie, G. S. K. [1 ]
Beverloo, B. [1 ]
Jauch, A. [3 ]
Hose, D. [3 ]
Schaafsma, R. [1 ]
Kersten, M. J. [1 ]
Delforge, M.
de Weerdt, O. [1 ]
van der Griend, R. [1 ]
Wijermans, R. W. [1 ]
Martin, Hans
van der Velde, H.
Lokhorst, Henk M. [1 ]
Goldschmidt, H. [3 ]
机构：
[1] HOVON, Rotterdam, Netherlands
[2] Erasmus MC, Rotterdam, Netherlands
[3] Univ Heidelberg, GMMG, D-6900 Heidelberg, Germany
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：243 / 244
页数：2
相关论文
共 36 条
  • [31] Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial
    Rosinol, Laura
    Teresa Cibeira, M.
    Martinez, Joaquin
    Victoria Mateos, Maria
    Jose Terol, M.
    de la Rubia, Javier
    Palomera, Luis
    de Arriba, Felipe
    Oriol, Albert
    Alegre, Adrian
    Besalduch, Juan
    de Paz, Raquel
    Garcia-Larana, Jose
    Diaz-Mediavilla, Joaquin
    Sureda, Anna
    Jose Lahuerta, Juan
    Miguel, J. F. San
    Blade, Joan
    BLOOD, 2008, 112 (11) : 244 - 244
  • [32] MM-SZ01 Study: A Prospective, Randomized, Controlled, Multicenter Phase III Clinical Study Which Compared Polyethylene Glycol Liposomal Doxorubicin Versus Doxorubicin Combined with Bortezomib and Dexamethasone (PDD regimen vs PAD regimen) in the Treatment of Newly Diagnosed Multiple Myeloma in China
    Wang, Qingqing
    Wu, Depei
    Fu, Chengcheng
    Yan, Shuang
    Jin, ChengHao
    Lu, Xuzhang
    Chen, Tao
    Li, Fei
    Xia, Zhongjun
    Li, Bingzhong
    BLOOD, 2022, 140 : 12614 - 12615
  • [33] Phase 2 randomized study of daratumumab (dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT)
    Lin, T.
    Hydutsky, L.
    Parros, H.
    Murphy, S.
    Pei, H.
    Londhe, A.
    Ukropec, J.
    Qi, M.
    Lutska, Y.
    Sharma, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-Rvd) Vs. Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
    Voorhees, Peter M.
    Costa, Luciano J.
    Reeves, Brandi
    Nathwani, Nitya
    Rodriguez, Cesar
    Lutska, Yana
    Hydutsky, Laura
    Pei, Huiling
    Ukropec, Jon
    Qi, Ming
    Linand, Thomas
    Richardson, Paul G.
    BLOOD, 2017, 130
  • [35] GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years
    Mateos, Maria-Victoria
    Paiva, Bruno
    Cedena Romero, Maria Teresa
    Puig, Noemi
    Sureda Balari, Anna Maria
    Oriol, Albert
    Ocio, Enrique M.
    Rosinol, Laura
    Gonzalez-Montes, Yolanda
    Jose Bargay, Juan
    Gonzalez Garcia, Esther
    Hernandez Garcia, Miguel Teodoro
    Ramirez, Angel
    Suarez-Cabrera, Alexia
    Blanchard, Maria-Jesus
    Garzon, Sebastian
    Casado Montero, Luis Felipe
    Cabanas Perianes, Valentin
    Perez De Oteyza, Jaime
    Gironella, Mercedes
    Martinez-Lopez, Joaquin
    Ana-Isabel-Teruel
    Delgado, Pilar
    Prieto, Elena
    Lahuerta Palacios, Juan Jose
    Blade, Joan
    San Miguel, Jesus
    BLOOD, 2023, 142
  • [36] Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
    Voorhees, Peter M.
    Rodriguez, Cesar
    Reeves, Brandi
    Nathwani, Nitya
    Costa, Luciano J.
    Lutska, Yana
    Hoehn, Daniela
    Pei, Huiling
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas
    Richardson, Paul
    BLOOD, 2018, 132
1234